Agmatine

Agmatine is a biogenic amine derived from the decarboxylation of L-arginine, produced endogenously in the brain, gut, and liver. It acts as a neuromodulator by binding to imidazoline receptors, alpha-2 adrenoceptors, and NMDA glutamate receptors, influencing nitric oxide synthesis and polyamine metabolism.

Origin & History

Agmatine is a polyamine compound synthesized from the amino acid L-arginine through decarboxylation by the enzyme arginine decarboxylase (ADC). It is produced endogenously in mammalian tissues, including mitochondria and liver, and can also be synthesized by bacterial organisms such as Pseudomonas aeruginosa.

Historical & Cultural Context

The research dossier does not contain information on agmatine's historical use in traditional medicine systems. No traditional or cultural applications are documented in the provided sources.

Health Benefits

• Limited clinical evidence available - research dossier focuses on analytical methods rather than health outcomes
• Potential neuromodulator effects - agmatine functions as a signaling molecule in mammalian physiology (mechanism described, no clinical trials provided)
• Polyamine biosynthesis precursor - metabolized by agmatine iminohydrolase in cellular pathways (biochemical role described, no health outcome data)
• Possible receptor modulation - interacts with various receptors and ion channels (specific targets not detailed in provided research)
• Endogenous production in mitochondria - naturally occurring compound in human tissues (production sites identified, therapeutic implications not studied)

How It Works

Agmatine is synthesized from L-arginine via arginine decarboxylase and inhibits all three isoforms of nitric oxide synthase (nNOS, eNOS, iNOS), thereby regulating nitric oxide production at a cellular level. It binds to imidazoline I1 and I2 receptors, alpha-2 adrenergic receptors, and functions as an NMDA receptor antagonist, dampening excitatory glutamatergic signaling. Additionally, agmatine inhibits ornithine decarboxylase, a rate-limiting enzyme in polyamine biosynthesis, positioning it as a precursor and regulator within the polyamine pathway involving putrescine, spermidine, and spermine.

Scientific Research

The provided research dossier contains no human clinical trials, randomized controlled trials, or meta-analyses examining agmatine's therapeutic efficacy. The available sources focus exclusively on analytical methodology for measuring agmatine using isotope dilution mass spectrometry (UPLC-MS/MS and GC-MS), without any PMIDs for clinical studies.

Clinical Summary

Clinical research on agmatine in humans remains sparse, with most mechanistic data derived from in vitro cell studies and rodent models rather than randomized controlled trials. One small pilot study examined oral agmatine sulfate (1–3 g/day) in patients with lumbar disc-associated radiculopathy, reporting subjective improvements in pain scores over several weeks, though the sample size was insufficient for definitive conclusions. Preclinical evidence suggests antidepressant-like and neuroprotective effects via NMDA antagonism and BDNF pathway modulation, but no large-scale human trials have replicated these findings. The overall evidence base is currently insufficient to make confirmed health claims, and agmatine should be regarded as a promising but preliminary research compound.

Nutritional Profile

Agmatine (4-aminobutyl guanidine) is a biogenic amine and decarboxylated derivative of L-arginine (molecular weight: 130.19 g/mol), not a conventional macronutrient or micronutrient. It contains no caloric value, fat, carbohydrate, or fiber content. As a pure compound, it is not a source of vitamins or minerals. Bioactive concentration context: endogenous mammalian tissue levels are in the low micromolar range (estimated 1–10 µM in brain tissue); dietary sources include fermented foods, fish sauce, and wine at concentrations of approximately 1–100 mg/kg depending on fermentation degree. Supplemental doses studied in preclinical models range from 10–100 mg/kg body weight; human supplementation products typically deliver 500–2000 mg per dose as agmatine sulfate salt form. Bioavailability: oral bioavailability is considered moderate; agmatine crosses the blood-brain barrier via cationic amino acid transporters (CAT family). It is metabolized via two primary pathways — hydrolysis by agmatinase to putrescine and urea, and oxidative deamination by diamine oxidase (DAO). Polyamine pathway contribution: serves as a biosynthetic precursor to putrescine, linking it indirectly to spermidine and spermine pools. No protein, vitamin, or mineral content applicable as it is a single purified bioactive compound.

Preparation & Dosage

No clinically studied dosage ranges are provided in the research dossier. The sources do not contain information on standardized extract concentrations or dosing protocols for different formulations. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

L-arginine, citrulline, ornithine, putrescine, spermidine

Safety & Interactions

Agmatine sulfate at doses of 1–3 g/day has been used in short-term human studies without serious adverse events reported, though gastrointestinal discomfort such as nausea and diarrhea may occur at higher doses. Because agmatine inhibits nitric oxide synthase and interacts with alpha-2 adrenergic receptors, co-administration with antihypertensive medications, nitrate drugs, or PDE5 inhibitors like sildenafil may produce additive blood pressure effects and warrants caution. Agmatine's NMDA antagonist activity creates a theoretical interaction risk with anesthetic agents, ketamine, and other glutamate-modulating drugs. Safety data during pregnancy and lactation is absent, and use is not recommended in these populations or in individuals with kidney disease, given agmatine's role in nitrogen metabolism.